Novo CEO accepts R&D setbacks as CagriSema posts more mixed data and Novo eyes M&A on August 05, 2026 acquisitions blood sugar control bolt-on CagriSema CEO Mike Doustdar Diabetes Mellitus, Non-Insulin-Dependent Eli Lilly Zepbound narrow sales R&D setbacks tirzepatide Wegovy pill Weight Loss ziltivekimab +
Novo Nordisk's Next-Gen Obesity Drug Outperforms Wegovy in Phase III Blood Sugar Control on February 03, 2026 blood sugar control CagriSema Novo Nordisk obesity drug Phase III semaglutide Wegovy +